Trial reportPediatrics international : official journal of the Japan Pediatric Society
Efficacy and Safety of Human Protein C Concentrate in Japanese Patients With Severe Congenital Protein C Deficiency.
Trial report in Pediatrics international : official journal of the Japan Pediatric Society. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04984889 (An Open-Label, Single-Dose, Phase 1/2 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Human Protein C), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
An Open-Label, Single-Dose, Phase 1/2 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Human Protein C (TAK-662) for the Treatment of Congenital Protein C Deficiency in Japanese Subjects Followed by an Extension Part
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundSevere congenital protein C deficiency (SCPCD) is a rare disorder associated with life-threatening thrombotic complications. Protein C concentrate is recommended for both acute and long-term management of SCPCD. However, no efficacy and safety data in Japanese patients have been reported.
methodsIn this extension phase of an open-label, phase 1/2 clinical trial (ClinicalTrials.gov: NCT04984889), Japanese patients with SCPCD could receive intravenous protein C concentrate for on-demand treatment, short-term prophylaxis, or long-term prophylaxis. Efficacy of on-demand treatment was assessed using a predefined efficacy evaluation scale. For prophylaxis, efficacy was assessed based on the occurrence of purpura fulminans and thromboembolic complications during prophylaxis treatment. Safety was evaluated by recording adverse events (AEs).
resultsAll five patients who completed the pharmacokinetics phase of the study participated in this extension phase (mean [SD] age: 15.2 [8.9] years). At data cutoff, four patients had received eight on-demand treatments of protein C concentrate for purpura fulminans; all were rated as effective. Protein C concentrate was administered for short-term prophylaxis in one patient undergoing tooth extraction, with no thromboembolic complications observed. Six AEs were reported in three patients who received on-demand treatment; none were treatment-related. No AEs were observed during short-term prophylaxis. There were no deaths or AEs leading to treatment discontinuation.
conclusionsProtein C concentrate was effective for on-demand treatment and short-term prophylaxis, and had an acceptable safety profile in this study population. These results support the use of protein C concentrate in the clinical management of patients with SCPCD in Japan.
trial registrationClinicalTrials.gov registration number: NCT04984889.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.